Hideaki Bando, MD, PhD, discusses the safety of trifluridine/tipiracil in patients with MRD following resection of CRC.
Hideaki Bando, MD, PhD
Advertisement
Hideaki Bando, MD, PhD is a medical oncologist in the Department of Gastroenterology and Gastrointestinal Oncology at the National Cancer Center Hospital East, in Japan.
Articles by Hideaki Bando, MD, PhD
Hideaki Bando, MD, PhD, discusses efficacy outcomes with TAS-102 as a pre-emptive treatment in patients with MRD-positive CRC following curative resection.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Dr Spencer on First-Line Chemo Selection in Metastatic Pancreatic Adenocarcinoma
4
2025 Data Across Gynecologic, Lung, and Hematologic Cancers Reshape Treatment Landscapes
5